Literature DB >> 17376783

Avidity of CD8 T cells sharpens immunodominance.

Amiran H Dzutsev1, Igor M Belyakov, Dmitry V Isakov, David H Margulies, Jay A Berzofsky.   

Abstract

In the course of viral infection, the immune system exploits only a fraction of the available CTL repertoire and focuses on a few of a myriad of potentially antigenic peptides. This phenomenon, known as immunodominance, depends on a number of factors, including antigen processing and transport, MHC binding, competition for antigen-presenting cells, availability of the CD8 T cell repertoire and other mechanisms that function largely by restricting the immune response. Here we elucidate a novel mechanism that increases the immunodominance of the epitope rather by enhancing the immune response. Using a peptide-specific MHC-restricted mAb and functional assays of CTL activation, we show that T cells with high avidity for the immunodominant, H-2D(d) restricted, P18-I10 epitope expand rapidly following immunization, and this expansion in turn determines the level of the P18-I10 epitope immunodominance. This proliferation has little dependence on the number of MHC-peptide complexes. Since most self-reactive T cells of high avidity are depleted in the thymus, the selection of immunodominant epitopes based on the expansion of high-avidity T cells in the periphery reduces the potential for autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376783     DOI: 10.1093/intimm/dxm016

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  15 in total

1.  Estimation of low frequency antigen-presenting cells with a novel RELISPOT assay.

Authors:  Amiran K Dzutsev; Igor M Belyakov; Dmitry V Isakov; Susan J Gagnon; David H Margulies; Jay A Berzofsky
Journal:  J Immunol Methods       Date:  2008-02-08       Impact factor: 2.303

Review 2.  Therapeutic cancer vaccines: current status and moving forward.

Authors:  Jeffrey Schlom
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

3.  Lack of IL-7 and IL-15 signaling affects interferon-γ production by, more than survival of, small intestinal intraepithelial memory CD8+ T cells.

Authors:  Dmitry Isakov; Amiran Dzutsev; Jay A Berzofsky; Igor M Belyakov
Journal:  Eur J Immunol       Date:  2011-12       Impact factor: 5.532

4.  Structural and functional correlates of enhanced antiviral immunity generated by heteroclitic CD8 T cell epitopes.

Authors:  Jonathan A Trujillo; Stephanie Gras; Kelly-Anne Twist; Nathan P Croft; Rudragouda Channappanavar; Jamie Rossjohn; Anthony W Purcell; Stanley Perlman
Journal:  J Immunol       Date:  2014-05-02       Impact factor: 5.422

5.  In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity.

Authors:  Ana Villegas-Mendez; Marina I Garin; Estela Pineda-Molina; Eugenia Veratti; Juan A Bueren; Pascal Fender; Jean-Luc Lenormand
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

6.  HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity.

Authors:  Benoît Vingert; Santiago Perez-Patrigeon; Patricia Jeannin; Olivier Lambotte; Faroudy Boufassa; Fabrice Lemaître; William W Kwok; Ioannis Theodorou; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

7.  Altered CD8(+) T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F(1) mice.

Authors:  Inge E A Flesch; Wai-Ping Woo; Yang Wang; Vijay Panchanathan; Yik-Chun Wong; Nicole L La Gruta; Tania Cukalac; David C Tscharke
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

8.  Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

Authors:  Linda S Wyatt; Igor M Belyakov; Patricia L Earl; Jay A Berzofsky; Bernard Moss
Journal:  Virology       Date:  2007-11-28       Impact factor: 3.616

Review 9.  Therapeutic cancer vaccines: past, present, and future.

Authors:  Chunqing Guo; Masoud H Manjili; John R Subjeck; Devanand Sarkar; Paul B Fisher; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

10.  Immunodomination during peripheral vaccinia virus infection.

Authors:  Leon C W Lin; Inge E A Flesch; David C Tscharke
Journal:  PLoS Pathog       Date:  2013-04-25       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.